ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....

Full description

Bibliographic Details
Main Authors: Hongbo Zhao, Yutang Huang, Jingjing Shi, Yi Dai, Lanxiang Wu, Honghao Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Pharmacology
Subjects:
ABC transporter
ABCC10
gefitinib
acquired resistance
non-small cell lung cancer
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01312/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01312/full

Similar Items